In a prospective postmarketing assessment, the use of tisagenlecleucel for treatment of adult patients with diffuse large B-cell lymphoma, lead to responses that were similar to studies of children and adolescents with B-cell acute lymphoblastic leukemia.
In an interview with Targeted Oncology during the 2019 SOHO Annual Meeting, Laura C. Michaelis, MD, discussed the currently approved JAK inhibitors and the future landscape for myelofibrosis, as well as treatment considerations for graft-versus-host disease.
Recent updates to the JULIET study, presented at the 2019 SOHO Annual Meeting, show that tisagenlecleucel has sustained benefit throughout the course of the trial with high response rates, and long duration in adults with relapsed/refractory diffuse large B-cell lymphoma.
In a retrospective study of patients with replaced or refractory Hodgkin lymphoma, checkpoint inhibition prior to haploidentical stem cell transplantation improved progression-free survival and risk for relapse, based on results presented at the 2019 SOHO Annual Meeting.
In an interview with Targeted Oncology during the 2019 SOHO Annual Meeting, Ruben Mesa, MD, discussed the JAKARTA and JAKARTA-2 studies and the implications their data have on the field of myelofibrosis.